Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (701)	6/21/2005 5:28:02 PM
From: Icebrg	Respond to of 946

Evidently they (or maybe he) have written off any chance of getting Xyotax to the market within a meaningful timeframe. Not surprising. But what does this indicate with regard to Pixantrone? I believe, that the CTIC strategy was to try to use Trisenox's sales- and marketing infrastructure as starting point, when they were going to expand with new drugs. Now, there doesn't seem to be much left to take care of Pixantrone sales, if the pivotal is succesful. So maybe this is also an indication that CTIC is planning to licence Pixantrone to someone else. Or maybe Aselage was just so fed up that he left without thinking much about future opportunities. Erik